Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-β activation

Atherosclerosis

Volumn 125, Issue 1, 1996, Pages 15-26

  Sato, Yoshihiro ^a   Kobori, Shozo ^a   Sakai, Masakazu ^a   Yano, Toshihiro ^a   Higashi, Takayuki ^a   Matsumura, Takeshi ^a   Morikawa, Wataru ^b   Terano, Tsuyoshi ^b   Miyazaki, Akira ^a   Horiuchi, Seikoh ^a   Shichiri, Motoaki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Apolipoprotein(a); Lipoprotein(a); Macrophage growth; TGF

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; GROWTH INHIBITION; GROWTH STIMULATION; LIPID OXIDATION; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT;

EID: 0030599003     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05829-7     Document Type: Article

References (51)

1. [1] Scanu AM, Fless GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709.
2. [2] Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904.
3. [3] Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991;115:209.
4. [4] Scanu AM, Edelstein C. Kringle-dependent structural and functional polymorphism of apolipoprotein (a). Biochim Biophys Acta 1995;1256:1.
5. [5] McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132.
6. [6] Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301.
7. [7] Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303.
8. [8] Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry 1989;28:2374.
9. [9] Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism 1992;41:1215.
10. [10] Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;267:4143.
11. [11] Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992;360:670.
12. [12] Jürgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb 1993;13:1689.
13. [13] Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655.
14. [14] Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci 1990;87:4600.
15. [15] Rosenfeld ME, Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 1990;10:680.
16. [16] Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis 1991;88:87.
17. [17] Yui S, Sasaki T, Miyazaki A, Horiuchi S, Yamazaki M. Induction of murine macrophage growth by modified LDLs. Arterioscler Thromb 1993;13:331.
18. [18] Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, Shichiri M, Horiuchi S. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994;269:31430.
19. [19] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801.
20. [20] Morikawa W, Iki R, Terano T, Funatsu A, Sugiuchi H, Uji Y, Okabe H. Measurement of Lp(a) with a two-step monoclonal competitive sandwich ELISA method. Clin Chem 1995;28:269.
21. [21] Ye SQ, Trieu VN, Stiers DL, McConathy WJ. Interactions of low density lipoprotein-2 and other apolipoprotein B-containing lipoproteins with lipoprotein(a). J Biol Chem 1988;263:6337.
22. [22] Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978;15:429.
23. [23] Wong WLT, Eaton DL, Berloui A. Fendly B, Hass PE. A monoclonal antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). Clin Chem 1990;36:192.
24. [24] Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. J Clin Invest 1987;80:458.
25. [25] Ueno S-I, Kobori S, Ide M, Suzaki K, Takeda H, Horiuchi S, Shichiri M. A specific binding site for lipoproteins containing apolipoprotein A-1 on human hepatoma cell line HepG2. Jpn J Med 1991;30:524.
26. [26] Armstrong VW, Walli AK, Seidel D. Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). J Lipid Res 1985;26:1314.
27. [27] Kobori S, Nakamura N, Uzawa H, Shichiri M. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan. Atherosclerosis 1988;69:81.
28. 2+-mediated oxidation. FEBS Lett 1992;314:199.
29. [29] Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem 1959;234:466.
30. [30] Suzaki K, Kobori S, Ide M, Sasahara T, Sakai M, Toyonaga T, Shinohara M, Miyazaki A, Horiuchi S, Takeda H, Shichiri M. Acetyl-low density lipoprotein receptors on rat mesangial cells. Atherosclerosis 1993;101:177.
31. 2+ -catalyzed oxidation of human low density lipoprotein. FEBS Lett 1989;257:435.
32. [32] Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins: I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 1972;260:212.
33. [33] Sasahara T, Kobori S, Kasho M, Sato Y, Nishikawa T, Yano T. Takeda H, Shichiri M. The metabolic fate of apolipoprotein A-I-containing lipoproteins internalized into HepG2 cells: resecreted lipoproteins as a potent inducer for cholesterol efflux. Atherosclerosis 1994;106:179.
34. [34] Hakamata H, Miyazaki A, Sakai M, Sakamoto Y-I, Matsuda H, Kihara K, Horiuchi S. Differential effects of an acyl-coenzyme A: cholesterol acyltransferase inhibitor on HDL-induced cholesterol efflux from rat macrophage foam cells. FEBS Lett 1995;363:29.
35. [35] Ikeda T, Lioubin MN, Marquardt H. Human transforming growth factor type β2: production by a prostatic adenocarcinoma cell line. purification, and initial characterization. Biochemistry 1987:26:2406.
36. [36] Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M. TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994;45:525.
37. [37] Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β: bioactivity neutralization and transforming growth factor β2 affinity purification. J Immunol 1989;142:1536.
38. [38] Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991;266:2459.
39. [39] Yashiro A, O'Neil J. Hoff HF. Insoluble complex formation of lipoprotein(a) with low density lipoprotein in the presence of calcium ions. J Biol Chem 1993;268:4709.
40. [40] Krempler F, Kostner GM, Roscher A, Bolzano K, Sandhofer F. The interaction of human apo B-containing lipoproteins with mouse peritoneal macrophages: a comparison of Lp(a) with LDL. J Lipid Res 1984;25:283.
41. [41] Williams KJ, Fless GM, Petrie KA, Synder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. J Biol Chem 1992;267:13284.
42. [42] Rumsey SC, Obunike JC, Arad Y, Deckelbaum RJ, Goldberg IJ. Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. J Clin Invest 1992;90:1504.
43. [43] Mulder M, Lombardi P, Jansen H, Van Berkel TJC, Frants RR, Havekes LM. Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun 1992;185:582.
44. [44] Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Liporotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest 1992;90:2013.
45. [45] Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84:5788.
46. [46] Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988;34:260.
47. [47] Vodovotz Y, Bogdan C, Paik J, Xie Q-W, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J Exp Med 1993;178:605.
48. [48] Chantry D, Turner M, Abney E, Feldmann M. Modulation of cytokine production by transforming growth factor-β. J Immunol 1989;142:4295.
49. [49] Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440.
50. [50] Bottaro DP, Rubin JS, Faletto DL, Chan AML, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptors as the c-met protooncogene product. Science 1991;251:802.
51. [51] Mason RJ, Leslie CC, McCormick-Shannon K, Deterding RR, Nakamura T, Rubin JS, Shannon JM. Hepatocyte growth factor is a growth factor for rat alveolar type II cells. Am J Respir Cell Mol Biol 1994;11:561.